TransDerm, a small biotech focused on developing a treatment for pachyonychia congenita (PC), has just kicked off a phase I trial of a new drug candidate designed to treat the rare skin condition.

Title: Lentiviral Transduced Dendritic Cells for RNAi
Patent Number: 8,530,153
Filed: March 10, 2011
Inventor: Sam Kam Pun Kung, University of Manitoba

Researchers from TransDerm, which is developing RNAi-based treatments for skin disorders including pachyonychia congenita, last month published a report on the development of an in vivo imaging approach that can be used to rapidly screen and optimize siRNA delivery techn

TransDerm is preparing to begin the toxicology studies needed to launch a phase I trial of an improved version of its siRNA-based treatment for pachyonychia congenita, or PC, and expects the study to begin next year, Gene Silencing News has learned.

TransDerm, a small firm developing RNAi-based treatments for rare skin disorders, said this week that it has been awarded a $4 million grant from the National Institutes of Health to develop a technology for siRNA delivery into the skin.

The two areas, which have opportunities RXi's CEO called "tremendous" and "significant," have been well worn by rival drug companies making similar bets including Sirnaomics, TransDerm, and Quark Pharmaceuticals.

An update on the RNAi drug pipelines for Alnylam, Calando, Pfizer, Quark, Silence Therapeutics, Sylentis, Tekmira, TransDerm, and Zabecor.

In addition to evaluating RXi's proprietary RNAi compounds, TransDerm will test delivery technologies from Traversa Therapeutics, Thermo Fisher Scientific, and Life Technologies.

Overview of key RNAi-based therapeutics currently in human trials


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.